Phase II Study of Blinatumomab in Patients With B-cell Lineage Acute Lymphocytic Leukemia With Positive Minimal Residual Disease
Phase of Trial: Phase II
Latest Information Update: 22 Jan 2018
At a glance
- Drugs Blinatumomab (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 14 Sep 2015 Planned primary completion date changed from 1 Nov 2020 to 1 Sep 2020, as reported by ClinicalTrials.gov.
- 14 Sep 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.
- 09 Jun 2015 New trial record